Symptomatic Early Neurosyphilis Among HIV-Positive Men Who Have Sex with Men -Four Cities, United States, January 2002-June 2004
Symptomatic early neurosyphilis is a rare manifestation of syphilis that usually occurs within the first 12 months of infection (1) . Most neurologic symptoms of early neurosyphilis result from acute or subacute meningitis, abnormalities in cranial nerve function, and inflammatory vasculitis leading to a cerebrovascular accident. Symptomatic early neurosyphilis essentially disappeared in the United States after the introduction of penicillin treatment for syphilis in the late 1940s but reappeared in the 1980s among persons with human immunodeficiency virus (HIV) infection (1) (2) (3) . The disease burden from neurosyphilis is unknown because national reporting of this disease is incomplete. Because the increase in syphilis cases during the past 5 years has occurred primarily among MSM, many of whom were infected with HIV, CDC conducted a review of possible neurosyphilis cases to describe the clinical course of symptomatic early neurosyphilis and to better characterize the risk for this illness among HIV-infected MSM. The review included health department records from four U.S. cities (Los Angeles, California; San Diego, California; Chicago, Illinois; and New York, New York) for the period January 2002-June 2004. This report describes the results of that review, which identified 49 HIV-positive MSM with symptomatic early neurosyphilis during that 30-month period. Among HIV-positive MSM with early syphilis, the estimated risk for having symptomatic early neurosyphilis was 1.7%, and the risk for having early neurosyphilis with persistent symptoms 6 months after treatment was 0.5%. These findings emphasize the importance of preventing syphilis in HIVinfected persons. HIV-infected persons with cranial nerve dysfunction or other unexplained neurologic symptoms should be evaluated for early neurosyphilis.
Possible neurosyphilis cases were identified using health department surveillance reports and interview records of all syphilis cases reported in the four cities during January 2002-June 2004. These records were selected for review if 1) records of early syphilis case interviews administered by disease investigators indicated neurologic signs or symptoms, 2) laboratory reports included cerebrospinal fluid (CSF) tests for neurosyphilis, or 3) the record indicated that the patient was treated with a regimen used for neurosyphilis (e.g., intravenous [IV] penicillin for 10-14 days). Next, additional data were abstracted from medical records and, when indicated, supplemented by interviews with the patients' physicians. The patients' HIV status and the sex of their sex partners were determined from medical records, syphilis case interview records, or information provided by the patients' physicians. Because of limited staff availability, a convenience sample of possible neurosyphilis cases was used for the reviews in New York and Chicago (sampling fractions were 0.68 and 0.55, respectively); cases were more likely to be included if they were reported by health-care providers who reported large numbers of syphilis cases.
A total of 170 possible neurosyphilis cases were reviewed in Los Angeles (74), New York (47), Chicago (32), and San Diego (17); 147 (86%) had serologic evidence of syphilis and met the CDC surveillance case definition for neurosyphilis* (4) (121 confirmed and 26 probable cases). Ninety-nine (67%) of these 147 cases were in patients with symptoms compatible with early neurosyphilis (e.g., cranial nerve dysfunction, acute meningitis, cerebrovascular accident, headache, or altered mental status of recent onset); of these, 57 (58%) were in patients identified as MSM, 49 (86%) of whom were reported to be HIV positive (39 with confirmed neurosyphilis and 10 with probable neurosyphilis) and included in the case-series analysis.
The 49 HIV-positive MSM with symptomatic early neurosyphilis had a mean age of 38.4 years (range: 21-50 years); 63% were non-Hispanic white, 18% were non-Hispanic black, 14% were Hispanic, and 5% were of other or unknown race/ ethnicity. Neurologic complaints were visual disturbances, 25 patients (51%); headache, 16 (32%); gait difficulty, two (4%); hearing loss, two (4%); meningismus, one (2%); altered mental status, one (2%); and unknown symptoms, two (4%). After medical evaluation, the final clinical diagnoses could be grouped into four previously reported syndromes (3): cranial nerve dysfunction (34), meningitis (six), meningovascular syndrome (two), and other syndromes (seven) (Table) .
At the time of neurosyphilis diagnosis, 23 (47%) patients had secondary syphilis, five (10%) had signs of secondary syphilis within 1 week after neurosyphilis diagnosis, 12 (24%) had early latent syphilis, and nine (18%) were reported as having late latent syphilis, including five patients who had nontreponemal syphilis serologic titers of >1:32, suggesting probable early syphilis. Twelve (24%) patients reported a previous history of syphilis; of these, nine had adequate previous penicillin treatment documented. Seven of the nine had follow-up nontreponemal titers; of these, six had at least a fourfold decline in titer, suggesting they had an appropriate response to treatment.
Neurosyphilis signs and symptoms often were the only indication that a patient had a syphilis infection; 53% (26 of 49) had no other signs or symptoms of syphilis (21 with latent syphilis and five who had initial signs of secondary syphilis within 1 week after neurosyphilis diagnosis). All patients had one or more lumbar punctures (median: one; range: one to four). Of the 28 patients who had received a radiologic * Information on CDC's surveillance case definition for neurosyphilis is available at http://www.cdc.gov/std/syphsurvreco.pdf. Confirmed: syphilis of any stage, a reactive serologic test for syphilis, and a reactive Venereal Disease Research Laboratory (VDRL) test in CSF. Probable: syphilis of any stage, a nonreactive VDRL test in CSF, and both of the following: 1) elevated CSF protein (>40 mg/dL) or leukocyte count (>5 cells/mm 3 ) in the absence of other known causes of these abnormalities and 2) clinical symptoms or signs consistent with neurosyphilis in the absence of other known causes of these abnormalities. examination of the brain (i.e., computerized tomography or magnetic resonance imaging), 11 (39%) had abnormal results. HIV infection was newly identified (i.e., within 45 days before or after the neurosyphilis diagnosis) in 12 (24%) patients. Among the 28 patients with HIV diagnosed more than 1 year before the onset of neurosyphilis symptoms, 11 (45%) were receiving highly active antiretroviral therapy (HAART) at the time of neurosyphilis diagnosis. Forty-two (86%) patients had been hospitalized (median number of hospital days: 7 days; range: 1-17 days). Forty-seven (96%) patients had received IV penicillin, consistent with CDC's Sexually Transmitted Disease Treatment Guidelines, 2006 (5), and 41 (81%) had documentation of receiving IV penicillin for at least 10 days. The median time from neurosyphilis symptom onset to start of treatment was 25 days (range: 2-256 days) (Table) . Symptoms often persisted months after treatment. Among the 49 patients, three had experienced a neurosyphilis relapse; all had been retreated. Among the remaining 46 patients, 37 (80%) had 6-month follow-up information available; of these, 11 (30%) had experienced persistent symptoms (Table) , other cranial nerves (e.g., diplopia or imbalance), acute meningitis (e.g., fever or meningismus), and other syndromes that were thought by the clinician to be manifestations of neurosyphilis. ¶ Measure obtained closest to date of diagnosis within the period 45 days before to 15 days after that date. ** Denominators based on 37 patients for whom 6-month follow-up was available; three patients with ocular neurosyphilis had a symptomatic neurosyphilis relapse after appropriate treatment and were not included in the persistent symptoms analysis. † † Data not available.
Editorial Note: Neurosyphilis is a serious condition that can involve substantial consumption of health-care resources and persistent disabilities for patients. In this case series of symptomatic early neurosyphilis among HIV-positive MSM, most of the patients were admitted to a hospital, received 10-14 days of treatment with IV penicillin, and likely had numerous office visits, expenses, and loss of work time. At 6-month follow-up, 30% of patients had persistence of their principal neurosyphilis symptom. Intensity of persistent symptoms compared with initial complaint was not determined systematically, and most patients were reported as improved, but some will likely have permanent disabilities (6) . No relationship was observed between persistent symptoms and promptness of neurosyphilis treatment or HIV-related immunodeficiency; however, only 49 patients were included in this case series.
Symptomatic early neurosyphilis is known to have protean manifestations and variable clinical presentations (7) (8) (9) (10) . Approximately 75% of the patients in this case series reported visual disturbances or new onset headaches, and 12% had acute meningitis syndrome with fever and meningismus. Approximately half of the patients had no other clinical signs or symptoms of syphilis, and the HIV infections in nearly one quarter were undiagnosed. Because the clinical spectrum of symptomatic early neurosyphilis is varied, health-care providers caring for MSM should consider neurosyphilis in the differential diagnosis of any patient with compatible signs or symptoms or any unexplained neurologic symptom. The recommended treatment for early neurosyphilis (symptomatic and asymptomatic) is aqueous crystalline penicillin G, 18-24 million units per day, administered as 3-4 million units intravenously every 4 hours or by continuous infusion, for 10-14 days, regardless of HIV status. † The likelihood that syphilis infection will progress to symptomatic early neurosyphilis in HIV-infected MSM is difficult to determine because neurosyphilis occurs in persons with previously undiagnosed and untreated syphilis. Estimates based on series of reported neurosyphilis cases, as in this analysis, might be inaccurate because certain neurosyphilis cases were undiagnosed or unreported and because the number of persons with undiagnosed syphilis is unknown. However, crude estimates from this analysis indicate a risk of 1.7% for having symptomatic early neurosyphilis and 0.5% for having symptomatic early neurosyphilis with persistent symptoms. † Additional treatment and follow-up recommendations are described in CDC's Sexually Transmitted Disease Treatment Guidelines, 2006 (5) . Available at http:// www.cdc.gov/std/treatment.
The findings in this report are subject to at least three limitations. First, cases reported from two cities (New York and Chicago) were selected as part of a convenience subsample and might reflect bias toward patients with more severe illness. Second, the number of HIV-positive MSM with symptomatic early neurosyphilis and the estimated population at risk (i.e., HIV-positive MSM with early syphilis) are underestimated. Thirteen possible symptomatic early neurosyphilis cases were not included because information on patients' HIV status or the sex of their sex partners was missing or because a CSF test was not documented. In addition, certain neurosyphilis and early syphilis cases likely were undiagnosed or unreported. Finally, because medical records were not standardized and had varying levels of completeness, establishing a relationship between clinical and laboratory findings is difficult. Prospectively collected data are needed to more clearly describe the complexities of symptomatic early neurosyphilis.
Health-care providers should be alert to signs and symptoms of neurosyphilis among MSM and should counsel MSM about the various symptoms of neurosyphilis and the risk for illness and permanent disability. Counseling about neurosyphilis and its consequences might promote safer sexual behaviors and decrease transmission of syphilis and other sexually transmitted infections.
Toxic Anterior Segment Syndrome
After Cataract Surgery -
Maine, 2006
Toxic anterior segment syndrome (TASS), an acute, noninfectious inflammation of the anterior segment of the eye, is a complication of anterior segment eye surgery; cataract extraction is the most common form of this type of surgery. Various contaminants, usually from surgical equipment or supplies, have been implicated as causes of TASS (1) . The syndrome typically develops within 24 hours after surgery and is characterized by corneal edema and accumulation of white cells in the anterior chamber of the eye. Although most cases of TASS can be treated successfully with topical steroids, topical nonsteroidal antiinflammatory agents, or both, the inflammatory response associated with TASS can cause serious damage to intraocular tissues, resulting in vision loss. In October 2006, the Maine Department of Health and Human Services (MDHHS) received a report of a cluster of TASS cases among outpatients who had undergone cataract surgery at a hospital in Maine. MDHHS and CDC investigated the cluster and worked with the treating ophthalmologist and the hospital to prevent additional cases. This report describes the results of that investigation and the subsequent prevention measures implemented. Although the specific cause of the outbreak was not identified, no additional cases were reported after two series of changes were made to the materials and equipment used for surgery. Prevention of TASS requires careful attention to solutions, medications, and ophthalmic devices and to cleaning and sterilization of surgical equipment because of the numerous potential causes of the condition (1).
On October 11, 2006, an ophthalmologist at a 25-bed community hospital in Maine noted that eight of 10 patients on whom he had performed outpatient cataract surgery that day had an unusual degree of inflammation and decreased visual acuity. On October 12, the hospital's infection-control practitioner reported the cases to MDHHS, which began an investigation.
The patients' clinical symptoms and subsequent response to topical steroids and topical nonsteroidal antiinflammatory medications were consistent with TASS. The eight patients included five women and three men with a median age of 78.5 years (range: 68-90 years). Cataract extractions were performed on the left eye of five patients and on the right eye of three patients. Intraocular lenses were inserted in all patients after phacoemulsification* of the cataract.
The ophthalmologist was board certified, had been practicing for 20 years, and was the only ophthalmologist at the hospital. He performed surgeries on one day each week (Wednesdays) and did not perform surgeries at other facilities. He had not previously had patients with TASS and reported that he had not made any changes in his surgical technique either before or after the outbreak.
Based on factors reported in previous outbreaks of TASS (1) , beginning October 12, the following steps were taken to prevent additional cases: 1) the epinephrine used during surgery was changed to a preservative-free formulation because only preservative-free epinephrine should be used during cataract surgery (1); 2) the solution for the ultrasonic bath used to clean surgical instruments was changed twice a day rather than once a day; 3) medications with lot numbers different from those used on October 11 were obtained for subsequent surgeries; 4) staffing for the operation room was changed to include personnel who had assisted the treating ophthalmologist with a greater number of surgeries; 5) the autoclave used to sterilize ophthalmic equipment was checked by a manufacturer's representative and determined to be functioning normally; 6) a topical iodine antiseptic was switched to single-use containers; and 7) a new tip for the phacoemulsification device was used for each patient. (Phacoemulsification tips had been sterilized previously for reuse up to a total of seven times, a practice that was compliant with the manufacturer's recommendations.)
After these steps were taken, the ophthalmologist performed phacoemulsification cataract surgery on four patients on October 18. Per hospital procedure, the patients were informed of the potential risks of the surgery, and informed consent was obtained; patients also were notified of the TASS cases from the previous week. All four patients had TASS after surgery. The patients included three women and one man with a median age of 68 years (range: 55-76 years).
Cataract surgeries were suspended until November 8. In addition to the steps already taken, the following actions were taken before surgeries resumed: 1) new (rather than reprocessed) cannulas (used for irrigation and aspiration during surgery) were used for each procedure; 2) a new lot of balanced salt solution (used to irrigate the surgical site) was obtained from the same manufacturer; 3) equipment removed from the ultrasonic cleaning bath was rinsed with sterile, distilled water rather than tap water; 4) use of an enzymatic cleaner in the ultrasonic bath was discontinued; and 5) a rapid test (Pyrosate ™ , Associates of Cape Cod, Inc., East Falmouth, Massachusetts) for the presence of endotoxin in the solution from the ultrasonic bath was performed and was positive on October 20. * During phacoemulsification, a small incision is made on the side of the cornea. A probe (i.e., phacoemulsification device) is inserted into the eye that emits ultrasonic waves, which break up the lens so that it can be removed by suction and an intraocular lens can be implanted. This technique requires a very small incision and results in rapid healing. Additional information is available from the National Institutes of Health, National Eye Institute, at http://www.nei. nih.gov/health/cataract/cataract_facts.asp.
Editorial Note:
Cataract extraction is one of the most common surgeries in the United States, with approximately 2 million procedures performed each year (3). The incidence of TASS is unknown, although cases have been reported in the medical literature more frequently in recent years. A nationwide outbreak in 2005 was attributed to a commercially distributed irrigating solution contaminated with endotoxin (4). The outbreak of TASS documented in this report was the first to be reported to MDHHS. Although TASS is not a reportable condition in Maine, the health department expects to be notified of any outbreaks of unusual disease.
TASS has numerous causes, and most cases are attributed to 1) contaminants on surgical instruments, resulting from improper or insufficient cleaning; 2) products introduced into the eye during surgery, such as irrigating solutions or ophthalmic medications; or 3) other substances that enter the eye during or after surgery, such as topical ointments or talc from surgical gloves (5) . Although certain outbreaks have been associated with specific causes (6) (7) (8) , the majority of outbreaks are resolved after comprehensive assessments of potential causes result in numerous changes to solutions, medications, and methods for reusing surgical equipment, as was the case in the outbreak described in this report. In this outbreak, although a rapid endotoxin test of the solution in the ultrasonic bath was positive, whether endotoxin was the specific cause of the outbreak is unknown because numerous other changes were made in solutions, medications, and cleaning protocols, all of which might have contributed to resolution of the outbreak. Prevention of TASS primarily depends on using appropriate protocols for cleaning and sterilizing surgical equipment and paying careful attention to all solutions, medications, and ophthalmic devices used during anterior segment surgery (5) . The American Society for Cataract and Refractive Surgery (ASCRS) recently published a guideline to prevent single-facility outbreaks of TASS (5). This bestpractice guideline provides procedures for cleaning and sterilizing intraocular equipment, including reused and reprocessed equipment, used during cataract surgery.
TASS outbreaks should be reported to state and local health departments. Assistance with investigating outbreaks can be obtained from CDC's Division of Healthcare Quality Promotion at telephone, 800-893-0485. In addition, ASCRS supports the Intermountain Ocular Research Center at the University of Utah to assist physicians and surgical centers with TASS prevention and treatment; assistance can be obtained from the center at telephone, 801-581-6586, or by e-mail, nick.mamalis@hsc.utah.edu. Assistance also can be obtained from the Emory University Eye Center at telephone, 404-778-5853, or by e-mail, ophthfe@emory.edu. TASS outbreaks that are caused by a specific product should be reported to the Food and Drug Administration's MedWatch Program: at telephone, (800) FDA-1088; website, http://www.fda.gov/ medwatch/report.htm.
Surveillance of Preconception Health Indicators Among Women Delivering Live-Born InfantsOklahoma, 2000-2003
Promoting preconception health of women is a key public health strategy in the United States to decrease morbidity and mortality associated with adverse maternal and infant outcomes. In 2006, CDC published 10 recommendations for improving the health of women before pregnancy (1); one recommendation proposed maximizing public health surveillance to monitor preconception health. Toward this end, data collected in Oklahoma (the only state to develop a detailed survey question on preconception health) during 2000-2003 from the Pregnancy Risk Assessment Monitoring System (PRAMS) were analyzed to 1) estimate the prevalence of women who did not report three selected preconception health indicators, (i.e., pre-pregnancy awareness of folic acid benefits,* multivitamin consumption, † and receipt of healthcare counseling § ) and 2) identify those subpopulations of women who were more likely not to report these indicators. Results of this analysis indicated that 21.5% of Oklahoma women with a recent live birth were not aware of folic acid benefits before they became pregnant, 73.5% did not consume multivitamins at least four times per week during the month before pregnancy, and 84.8% did not receive preconception counseling from a health-care provider. Subpopulations of women with characteristics (at the time of conception) significantly associated (p<0.05) with not reporting at least two of the three indicators included those who were younger, were unmarried, had <12 years of education, had no health insurance, had an unintended pregnancy, or had a previous live birth. Other states might use this analysis to help develop preconception health questions to be included in their own PRAMS surveys; Oklahoma state and local health officials can use the results to help prioritize preconception health objectives and identify subpopulations of women in need of targeted programs.
PRAMS is an ongoing state-and population-based surveillance system designed to monitor self-reported behaviors and experiences that occur before, during, and after pregnancy among women who deliver live-born infants. PRAMS is administered by CDC in collaboration with state health departments and follows standard data-collection procedures. ¶ Self-reported survey data are linked to birth certificate data and weighted for sample design, nonresponse, and noncoverage. The PRAMS questionnaire consists of core questions that appear on all state surveys and statedeveloped questions tailored to meet the individual needs of states. Additional details regarding PRAMS have been described previously (4) .
Data from Oklahoma were analyzed because Oklahoma was the only state to develop a detailed question for its PRAMS questionnaire regarding preconception health: "Before you became pregnant with your new baby, did any of these things happen? a) You heard or read that taking vitamins with folic acid could help prevent some birth defects; and b) you received advice or counseling from a health-care provider to prepare for becoming pregnant." Preconception multivitamin use was ascertained from a PRAMS core question used by all states: "In the month before you got pregnant with your new baby, how many times a week did you take a multivitamin (a pill that contains many different vitamins and minerals)?" The percentage of women who did not report each of these indicators was estimated overall and stratified by selected characteristics. To identify significant associations between women in subpopulations with selected characteristics and not reporting each indicator, multiple logistic regression was used to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs). All calculations were performed using data weighted to Oklahoma population data. The average annual weighted survey response rates during 2000-2003 was 81.3% (range: 79.9%-83.7%).
Results indicated that, during 2000-2003, among Oklahoma women who had recently delivered a live-born infant, 21.5% were not aware of folic acid benefits before they became pregnant, 73.5% did not consume multivitamins at least four times per week during the month before pregnancy, and 84.8% did not receive preconception counseling from a health-care provider (Table) . Lack of awareness of folic acid benefits before pregnancy was greatest among women who were aged <20 years (39.4%), black (40.7%), or enrolled in Medicaid (39.2%). The prevalence of not consuming multivitamins at least four times a week in the month before preg- ¶ The PRAMS sample of women who have had a recent live birth is drawn from the state's birth certificate files. Each participating state samples 1,300-3,400 women per year. Women in certain smaller populations at higher risk are sampled at a higher rate to ensure adequate data. Selected women are first contacted by mail; women who do not respond to repeated mailings are subsequently contacted and interviewed by telephone. In Oklahoma, a total of 7,680 women completed the PRAMS survey during 2000-2003.
* Increased consumption of folic acid (a member of the vitamin B complex) before conception and during the first trimester of pregnancy can reduce the incidence of neural tube defects by 50%-70% (2,3). The U.S. Public Health Service recommends that all women of childbearing age consume >400 µg of folic acid daily through either supplementation or fortified foods (2). † Most commonly available multiple vitamins contain >400 µg folic acid. § Since 2006, CDC has recommended that one preconception visit for women planning pregnancy be offered as a component of maternity care, to enable women to receive risk assessment, health education, and specific interventions to address identified risks before conception (1). nancy was greatest among women who were aged <20 years (87.4%), who were unmarried (85.2%), who had <12 years of education (83.9%), who had no health insurance (84.1%), or whose pregnancy was unintended (84.4%). Not receiving preconception counseling was most common among women who were Hispanic (91.4%), who were unmarried (90.1%), who had no health insurance (92.3%), or whose pregnancy was unintended (93.4%).
Subpopulations of women with characteristics significantly associated with lack of pre-pregnancy awareness of folic acid benefits included those who were aged <20 (AOR = 1.9), 20-24 (AOR = 1.5), or >35 (AOR = 1.5) years, compared with those aged 25-34 years; who were black (AOR = 2.0) or American Indian (AOR = 1.5), compared with those who were white; who were unmarried (AOR = 1.8), compared with those who were married; who had <12 (AOR = 2.3) or 12 (AOR = 2.1) years of education, compared with those who had >12 years of education; or whose pregnancy was unintended (AOR = 1.5), compared with those whose pregnancy was intended (Table) . Subpopulations of women with characteristics significantly associated with not consuming multivitamins at least four times per week 1 month before pregnancy included those who were aged <20 (AOR = 1.8) or 20-24 (AOR = 1.7) years; who were unmarried (AOR = 1.5); who had 12 years of education (AOR = 1.5); who had no health insurance (AOR = 1.7), compared with those who had private insurance; whose pregnancy was unintended (AOR = 2.6); or who had a previous live birth (AOR = 1.4), compared with those who did not Editorial Note: Educational activities and media campaigns have been conducted since the early to mid-1990s to increase awareness of the importance of folic acid in preventing neural tube defects. The U.S. Public Health Service recommends that all women of childbearing age consume >400 µg of folic acid daily through either supplementation or fortified foods (2) . Findings in this report suggest that 78.5% of Oklahoma mothers during 2000-2003 were aware of the benefits of folic acid consumption. This represents an increase from 1995, when 66.4% of Oklahoma PRAMS participants reported folic acid awareness (5). However, lack of awareness was greater among women in certain subpopulations. For example, women with <12 years of education were more than twice as likely as women with >12 years of education to not be aware of folic acid benefits.
Despite high awareness of the benefits of taking vitamins with folic acid, 73.5% of women sampled (68.8% of those who were aware of folic acid's benefits and 87.9% of those who were not aware) did not consume multivitamins at least four times per week during the 1 month before pregnancy, although multivitamins typically contain folic acid (6) . This finding suggests that, although most women were aware of folic acid's value in preventing certain birth defects, they might not have known that folic acid should be taken before conception to maximize benefits. This hypothesis was supported by findings from a national telephone survey of women aged 18-45 years that determined that, although 79% of respondents had heard or read about folic acid, only 10% of these women knew that folic acid should be taken before pregnancy (7) . The fact that women with unintended pregnancies were 2.6 times as likely as women with intended pregnancies not to consume multivitamins at least four times per week during the month before conception might be of particular concern, considering that half of all pregnancies in the United States are unintended (8) and unintended pregnancies are more likely to have complications (9).
With regard to the third indicator, 84.8% of the women sampled (72.1% with intended pregnancies and 93.4% with unintended pregnancies) did not receive preconception counseling from a health-care provider. In addition, 92.3% of women with no health insurance and 91.4% of Hispanic women did not receive counseling. Since 2006, CDC has recommended offering, as a component of maternity care, one pre-pregnancy visit for women planning pregnancy (1). Examples of preconception interventions for improving pregnancy outcomes that might be incorporated into preconception counseling include folic acid supplementation, rubella and hepatitis B vaccination, screening and treatment for human immunodeficiency virus/acquired immunodeficiency syndrome and sexually transmitted infections, smokingcessation counseling, diabetes management, and obesity control (1) . In this analysis, women with a previous live birth were 1.9 times as likely as women without a previous live birth not to receive preconception counseling. Although women with a previous live birth likely believe they are better prepared for pregnancy and therefore might not seek counseling, new health concerns warranting risk assessment and appropriate interventions can emerge during interconception care; therefore, preconception counseling is recommended for all women planning pregnancy.
The findings in this report are subject to at least four limitations. First, these preconception health indicators are selfreported after delivery, and responses might be subject to recall bias. Second, assessment of multivitamin consumption might not accurately reflect intake of folic acid. Although most commonly available multivitamins contain the daily recommended amount of folic acid (6), folic acid can be consumed through other means (e.g., fortified foods or a supplement containing only folic acid). Third, although population based, these findings are generalizable only to mothers with recent live births in Oklahoma. Finally, because of the cross-sectional design of the study, the observed associations cannot be presumed to be causal.
Oklahoma state and local health officials can use these results to prioritize preconception health objectives. Although pre-pregnancy awareness of folic acid benefits was high, consumption of multivitamins was low, as was receipt of preconception counseling, even among those women whose pregnancy was intended. These data also can be used to identify subpopulations of women in need of outreach during the preconception period. For example, women who are younger, are unmarried, have less education, or are not planning pregnancy might benefit from targeted outreach to improve prepregnancy awareness of folic acid benefits and multivamin consumption. To improve rates of preconception counseling, access to care should be addressed, as well as tailoring messages to women who have had previous live births and might believe that counseling is not necessary. In addition, nearly 60% of pregnancies in Oklahoma were categorized as unintended, and those not planning pregnancy had increased odds of not being aware of the benefits of folic acid before pregnancy, not taking a multivitamin at least four times per week during the month before pregnancy, and not receiving preconception counseling; therefore, efforts to promote preconception health should target all women of reproductive age who are capable of becoming pregnant (10). 
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